103935-47-3

Usage

Uses

Used in Organic Synthesis:
2-Bromoethyl trifluoromethanesulphonate is used as an alkylating agent in organic synthesis for the functionalization of alcohols and amines. It facilitates the formation of carbon-carbon or carbon-nitrogen bonds, which is crucial for the synthesis of various organic compounds.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 2-Bromoethyl trifluoromethanesulphonate is utilized for the synthesis of a range of drugs. Its alkylating properties are harnessed to create new drug molecules with specific therapeutic effects.
Used in Polymer Production:
2-Bromoethyl trifluoromethanesulphonate also serves as a cross-linking agent in the production of polymers. It helps in creating stable polymer structures by forming covalent bonds between polymer chains, enhancing the material's properties such as strength and durability.
Safety Precautions:
Given its toxic and corrosive nature, it is imperative to handle 2-Bromoethyl trifluoromethanesulphonate with extreme care. Adequate safety measures, including the use of personal protective equipment and proper disposal methods, must be implemented to minimize exposure and potential hazards.

Upstream product

• 74-85-1 ethene 
• 35895-70-6 tetrabutylammonium trifluoromethylsulfonate 
• 33454-82-9 lithium trifluoromethanesulfonate 
• 108-48-5 2,6-dimethylpyridine 
• 141072-57-3 1-bromoethanol 
• 358-23-6 trifluoromethylsulfonic anhydride 
• 540-51-2 2-bromoethanol 
• 2923-28-6 silver trifluoromethanesulfonate 
• 106-93-4 ethylene dibromide 

Downstream Products

• 189452-25-3 (2R,4S)-3-benzoyl-4-bromoethyl-4-methyl-2-phenyl-1,3-oxazolidin-5-one 
• 247129-85-7 (2-bromoethyl)(diphenyl)sulfonium trifluoromethanesulfonate 
• 323192-77-4 (2R,4R)-2-phenyl-4-(2-bromoethyl)-4-((4-phenylmethoxy)phenyl)-5-oxo-3-oxazolidinecarboxylic acid methyl ester 
• 405906-74-3 {(Z)-(8S,11S)-16-Benzyloxy-3-[2-(2-bromo-ethoxy)-phenyl]-5-cyano-8-isopropyl-10-oxo-18-oxa-6,9-diaza-tricyclo[11.3.1.1^4,7]octadeca-1⁽¹⁶⁾,2,4,6,13⁽¹⁷⁾,14-hexaen-11-yl}-carbamic acid tert-butyl ester 
• 890022-42-1 (2S,4R)-4-Benzyl-4-(2-bromo-ethyl)-2-tert-butyl-5-oxo-oxazolidine-3-carboxylic acid allyl ester 
• 106114-50-5 1-(2-fluoroethyl)-4-phenylpiperazine 
• 190003-04-4 tert-butyl (3S)-3-(benzylamino)-3-phenylpropanoate 
• 1301167-89-4 2-[4-[1-(2-⁽¹⁸⁾F-fluoroethyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]phenoxymethyl]-3,5-dimethylpyridine 
• 1320293-09-1 C₂₄H₂₃⁽¹⁸⁾FN₄O 
• 1278457-70-7 methyl (2S)-2-(benzyl-(2-bromo-ethyl)-amino)-3-(4-tertbutoxy-phenyl)-propionate 
• 873200-46-5 N-bromoethyl-N-(tert-butyloxycarbonylmethyl)-L-aspartic acid β-benzyl α-tert-butyl ester 
• 216772-52-0 2,3,4,5-tetra-O-benzyl-N-(2-bromoethyl)-D-arabinonamide 

Relevant academic research and scientific papers

Vinyl Thianthrenium Tetrafluoroborate: A Practical and Versatile Vinylating Reagent Made from Ethylene

The use of vinyl electrophiles in synthesis has been hampered by the lack of access to a suitable reagent that is practical and of appropriate reactivity. In this work we introduce a vinyl thianthrenium salt as an effective vinylating reagent. The bench-stable, crystalline reagent can be readily prepared from ethylene gas at atmospheric pressure in one step and is broadly useful in the annulation chemistry of (hetero)cycles, N-vinylation of heterocyclic compounds, and palladium-catalyzed cross-coupling reactions. The structural features of the thianthrene core enable a distinct synthesis and reactivity profile, unprecedented for other vinyl sulfonium derivatives.

Pd/Cu-Catalyzed Vinylation of Terminal Alkynes with (2-Bromoethyl)diphenylsulfonium Triflate

The potential of (2-bromoethyl)diphenylsulfonium triflate to be a powerful vinylation reagent was determined by the Sonogashira cross-coupling reactions with terminal alkynes. The vinylation proceeded smoothly at 25 °C under Pd/Cu catalysis to afford a variety of 1- and 2-unsubstituted 1,3-enynes in moderate to excellent yields. This protocol represents the first application of (2-haloethyl)diphenylsulfonium triflate as a CH═CH2 transfer source in organic synthesis.

SPIRO-SULFONIMIDAMIDE DERIVATIVES AS INHIBITORS OF MYELOID CELL LEUKEMIA-1 (MCL-1) PROTEIN

The disclosure is directed to compounds of Formula (I). Pharmaceutical compositions comprising compounds of Formula (I) as well as methods of their use and preparation, are also described.

ALPHA-HYDROXY PHENYLACETIC ACID PHARMACOPHORE OR BIOISOSTERE MCL-1 PROTEIN ANTAGONISTS

Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, or a stereoisomer thereof; and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.

TRIOXACARCIN-ANTIBODY CONJUGATES AND USES THEREOF

Provided herein are trioxacarcin-antibody drug conjugates of Formula (I): and pharmaceutically acceptable salts thereof, wherein R7 is -L-B, wherein L is a linking group, and B is an antibody or antibody fragment. Also provided are methods of preparing the antibody-drug conjugates, pharmaceutically acceptable compositions thereof, and methods of their use and treatment. Further provided are precursors to the trioxacarcin- antibody drug conjugates (e.g., compounds of Formula (II), novel trioxacarcins without an antibody conjugated thereto), pharmaceutical compositions thereof, and methods of their use and treatment.

Salts and crystals of EGFR (epidermal growth factor receptor) inhibitor and their preparation methods

The invention discloses salts and crystals of an EGFR (epidermal growth factor receptor) inhibitor and their preparation methods, as well as application of the salts and crystals in preparation of drugs to treat non-small cell lung cancer.

Annulation of β-naphthols and 4-hydroxycoumarins with vinylsulfonium salts: Synthesis of dihydrofuran derivatives

A new synthetic approach to dihydrofuran derivatives via the annulation reaction of β-naphthols and 4-hydroxycoumarins with vinylsulfonium salts has been developed. A variety of dihydrofuran derivatives were prepared in moderate to good yields under mild conditions. The products could be readily transformed to the corresponding furans via the dehydrogenation with DDQ.

FUSED-RING OR TRICYCLIC ARYL PYRIMIDINE COMPOUND USED AS KINASE INHIBITOR

Disclosed is a fused-ring or tricyclic aryl pyrimidine compound used as a mutation selectivity EGFR inhibitor. Specifically, disclosed is a compound represented by formula (I) and used as an EGFR inhibitor or a pharmaceutically acceptable salt thereof.

COMPOUNDS THAT INHIBIT MCL-1 PROTEIN

Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.

COMPOUNDS AND METHODS FOR INHIBITING PRODUCTION OF TRIMETHYLAMINE

The invention provides a method of inhibiting the conversion of choline or carnitine to trimethylamine (TMA) and lowering TMAO in an individual comprising administering to the individual a composition comprising a compound set forth in FORMULA (I): The in